AEZS - Aeterna Zentaris Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Aeterna Zentaris Inc.

315 Sigma Drive
Suite 302D
Summerville, SC 29486
United States

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Klaus Paulini Ph.D.Pres, CEO & Director219.68kN/AN/A
Ms. Leslie Auld C.A., CPA, M.B.A., MBA, CPA, CASr. VP & CFO194.06kN/AN/A
Dr. Nicola Ammer M.D.Chief Medical Officer & VP of Clinical Devel.160.41kN/AN/A
Dr. Matthias GerlachVP of Manufacturing & Supply Chain182.26kN/AN/A
Mr. Olaf AlthausGM & MDN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology and endocrinology. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

Corporate Governance

Aeterna Zentaris Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.